Government rule currently prevent allowing drugs prices to fluctuate based on the stage in which the drug is being used, but changing sentiment may allow for more creativity in how drugs are priced, according to Scott Gottlieb, MD.
Kavita Patel, MD, MS, thinks granting Medicare the ability to negotiate drug prices is unlikely, but indicate-based pricing, or something in that direction, could happen. However, John L. Fox, MD, MHA, noted that the challenge with indication-based pricing is explaining what it is and then administering it.
“So I can see a 10% co-insurance if you have stage 4 metastatic cancer first line, but, I'm sorry, you’ve got metastatic recurrence disease and now you are second line and it's going to go up to 20%,” he said.
Dr Gottlieb moved the conversation to formulary design and what changes are expected to be seen. Ted Okon, explained that the Community Oncology Alliance has seen narrowing networks and plans going into more of a formulary basis.
“The problem in in oncology that's tougher to do,” he said. “But I think what’s going to sort of change some of the rubric here is the advent of biosimilar. You’re getting more biologic completion here and CMS is really adamant about—whether that is going to destroy a nascent industry or not—but they are really adamant about putting all of those under the same codes and allowing prices to be driven down and using it that way.”
HIVconsvX Vaccine Shows Safety, Immune Response in People on ART
March 10th 2025This research on a T-cell–targeting vaccines in HIV has implications for future study design to incorporate consideration of age and years on antiretroviral therapy (ART) to evaluate the level of immune reconstitution.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Ruxolitinib Cream Shows Long-Term Safety in AD, Potential for PN Treatment
March 8th 2025Two posters presented at the 2025 American Academy of Dermatology Annual Meeting reaffirmed the impact of ruxolitinib cream (Opzelura; Incyte) in atopic dermatitis (AD), while late-breaking research highlighted its potential efficacy in prurigo nodularis (PN).
Read More